Drug profile · INN
bumetanide
BUMETANIDE
bumetanide (BUMETANIDE) is a sodium-(potassium)-chloride cotransporter 2 inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: nasal. Current US regulatory status: approved.
Drug details — bumetanide
- US status
- approved
- Class
- —
- Route
- NASAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.89
Quick answer
bumetanide (BUMETANIDE) is a sodium-(potassium)-chloride cotransporter 2 inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: nasal. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium-(potassium)-chloride cotransporter 2 inhibitor
Primary target: Solute carrier family 12 member 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is bumetanide?
bumetanide (BUMETANIDE) is a sodium-(potassium)-chloride cotransporter 2 inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: nasal. Current US regulatory status: approved.
What is the brand name for bumetanide?
BUMETANIDE is a marketed brand name for bumetanide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bumetanide?
bumetanide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.